Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Artículo científico |
| Language: | en |
| Published: |
Marine drugs
2025
|
| Subjects: | |
| Online Access: | https://pubmed.ncbi.nlm.nih.gov/39997210/ |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Table of Contents:
- Marine Phytoplankton Bioactive Lipids and Their Perspectives in Clinical Inflammation. Cutolo, Edoardo Andrea Campitiello, Rosanna Di Dato, Valeria Orefice, Ida Angstenberger, Max Cutolo, Maurizio Phytoplankton Humans Lipids Inflammation Animals Microalgae Aquatic Organisms Lipid Metabolism Marine phytoplankton is an emerging source of immunomodulatory bioactive lipids (BLs). Under physiological growth conditions and upon stress challenges, several eukaryotic microalgal species accumulate lipid metabolites that resemble the precursors of animal mediators of inflammation: eicosanoids and prostaglandins. Therefore, marine phytoplankton could serve as a biotechnological platform to produce functional BLs with therapeutic applications in the management of chronic inflammatory diseases and other clinical conditions. However, to be commercially competitive, the lipidic precursor yields should be enhanced. Beside tailoring the cultivation of native producers, genetic engineering is a feasible strategy to accrue the production of lipid metabolites and to introduce heterologous biosynthetic pathways in microalgal hosts. Here, we present the state-of-the-art clinical research on immunomodulatory lipids from eukaryotic marine phytoplankton and discuss synthetic biology approaches to boost their light-driven biosynthesis.